A systematic review of inhaled intranasal therapy for central nervous system neoplasms: An emerging therapeutic option

Journal of Neuro-Oncology

Volumn 116, Issue 3, 2014, Pages 437-446

  Peterson, Asa ^a   Bansal, Amy ^a   Hofman, Florence ^a   Chen, Thomas C ^a   Zada, Gabriel ^a  

^a LAC USC MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; CNS tumor; Inhalant; Intranasal; Neoplasm; Pharmacokinetics

Indexed keywords

ADMINISTRATION, INTRANASAL; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS;

EID: 84894042493     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1346-5     Document Type: Review

References (47)

1. Lochhead JJ, Thorne RG (2011) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64(7):614-628. doi: 10.1016/j.addr.2011.11.002
2. Behl CR, Pimplaskar HK, Sileno AP et al (1998) Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 29:89-116
3. Illum L (2003) Nasal drug delivery - possibilities, problems and solutions. J Controll Release 87(1-3):187-198
4. Illum L (2004) Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56:3-17
5. Talegaonkar S, Mishra PR (2004) Intranasal delivery: an approach to bypass the blood brain barrier. Indian J Pharmacol 36(3):140-147
6. Mistry A, Stolnik S, Illum L (2009) Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146-157
7. Thorne RG, Emory CR, Ala TA, Frey QH (1995) Quantitative analysis of the olfactory pathway for drug delivery to brain. Brain Res 692:278-283
8. Dhuria S, Hanson L, Frey W (2009) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99(4):1654-1673
9. Frey WH, Liu J, Chen X et al (1997) Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv 4:87-92
10. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH (2004) Delivery of insulin-like growth factor-1 to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481-496
11. Fliedner S, Schulz C, Lehnert H (2006) Brain uptake of intranasally applied radioiodinated leptin in wistar rats. Endocrinology 147:2088-2094
12. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5(6):514-516
13. Fehm HL, Perras B, Smolnik R, Kern W, Born J (2000) Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology? Eur J Pharm 405:43-54
14. Lundstrom K (2001) Alphavirus vectors for gene therapy applications. Curr Gene Ther 1:19-29
15. Reitz M, Demestre M, Sedlacik J, Meissner H, Fiehler J, Kim SU, Westphal M, Schmidt NO (2012) Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Trans Med 1(12):866-873
16. Liu L, Eckert MA, Riazifar H, Kang D-K, Agalliu D, Zhao W (2013) From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier?. Stem Cells Int 2013:435093. doi: 10.1155/2013/435093
17. Chen J, Zhang C, Liu Q (2012) Solanum tuberosum lectin-conjugated plga nanoparticles for nose-to-brain delivery. In vivo and in vitro evaluations. J Drug Target 20(2):174-184
18. Jansson D, Bjork E (2002) Visualization of in vivo olfactory uptake and transfer using fluorescein dextran. J Drug Target 10:379-386
19. Kanazawa T, Tanaka K, TaKi H (2011) Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm Res 28(9):2130-2139
20. da Fonseca CO, Landeiro JA, Clark SS, Quirico-Santos T et al (2006) Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg Neurol 65(Suppl 1):2
21. Balassiano TI, de Paulo AS, Silva HN, Cabral CM, Gibaldi D, Bozza M, da Fonseca OC, da Costa Carvalho DGM (2002) Effects of perillyl alcohol in glial C6 cell line in vitro and anti-metastatic activity in chorioallantoic membrane model. Int J Mol Med 10:785-788
22. Bailey HH, Attia S, Love RR et al (2007) Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol 62:149-157
23. da Fonseca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T (2008) Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp (Warsz) 56(4):267-276
24. da Fonseca CO, Masini M, Futuro D, Caetano R, Gattass CR, Quirico-Santos T (2006) Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review. Surg Neurol 66:611-615
25. da Fonseca CO, Silva JT, Lins IR, Simão M, Arnobio A, Futuro D, Quirico-Santos T (2009) Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Invest New Drugs 27(6):557-564
26. da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, RochaGattass C (2008) Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 70:259-267
27. da Fonseca CO, Simao M, Lins IR, Caetano RO, Futuro D, Quirico-Santos T (2010) Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 137:287-293
28. Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn G, Xu T, Petasis NA, Louie SG, Schonthal AH, Hofman FM, Chen TC (2012) Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther 11(11):2462-2472
29. Balachandran S, Barber GN (2004) Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5:51-65
30. Wollmann G, Rogulin V, Simon I, Rose JK, van den Pol AN (2010) Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol 84(3):1563-1573
31. Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN (2008) Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 28(8):1882-1893
32. Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I et al (2010) Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 21:185-196
33. Cotmore ST, Tattersall P (2007) Parvoviral host range and cell entry mechanisms. Adv Virus Res 70:189-232
34. Kiprianova I, Thomas N, Ayache A et al (2011) Regression of glioma in rat models by intranasal application of parvovirus. Clin Cancer Res 17:5333-5342
35. Le S, Zhu JJ, Anthony DC, Greider CW, Black P (1998) Telomerase activity in human gliomas. Neurosurgery 42(5):1120-1124
36. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH, Deen DF (2008) New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 10(2):112-120
37. Sakane T, Yamashita S, Yata N, Sezaki H (1999) Transnasal delivery of 5-fluorouracil to the brain in the rat. J Drug Target 7:233-240
38. Shingaki T, Sakane T, Yamashita S, Sezaki H, Yoshiharu T, Shoubu S (1999) Transnasal delivery of anticancer drugs to the brain tumor: a new strategy for brain tumor chemotherapy. Drug Deliv System 14:365-371
39. Shingaki T, Inoue D, Furubayashi T, Sakane T, Katsumi H, Yamamoto A, Yamashita S (2010) Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy. Mol Pharm 7(6):1561-1568
40. Wang F, Jiang X, Lu W (2003) Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 263:1-7
41. Wang D, Gao Y, Yun L (2006) Study on brain targeting of raltitrexed following intransal administration in rats. Cancer Chemother Pharmacol 57:97-104
42. van Seters AP, van Dulken H, de Keizer RJ, Vielvoye GJ (1989) Symptomatic relief of meningioma by buserelin maintenance therapy. The Lancet 11:564-565
43. Weeke J, Christensen SE, Orskov H, Kaal A, Pedersen MM, Illum P, Harris AG (1992) A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. J Clin Endocrinol Metab 75(1):163-169
44. Invitti C, Fatti L, Camboni MG, Porcu L, Danesi L, Delitala G, Cavagnini F (1996) Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients. J Endocrinol Invest 19(8):548-555
45. Lerner E, Zanten E, Stewart G (2004) Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration. J Drug Target 12(5):273-280
46. Sharma G, Mishra AK, Mishra P, Misra A (2009) Intranasal Cabergoline: pharmacokinetics and pharmacodynamic studies. AAPS Pharmscitech 10(4):1321-1330
47. Loh JA, Verbalis JG (2008) Disorders of water and salt metabolism associated with pituitary disease. Endocrinol Metab Clin North Am 37:213-234